University of Southern California


COVID-19 Clinical Trials

To add your information, please fill out this form.
Please look here for a list of potential COVID-19 Collaborators by Area of Expertise.

Subarna Biswas  

A Multicenter, Prospective, Randomized, Open-Label Phase 2 Study to Assess Safety and Efficacy of Ang-3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia.

Michael Bowdish  
Zea Borok  
Perren Cobb  

A Multicenter, double blind, parallel design, placebo controlled trial to Assess Safety and Efficacy of Mesenchymal stem cells for the treatment of moderate to severe COVID-19 acute respiratory distress syndrome.

Richard J. Castriotta  
Aarya Kafi  
Lynn Fukushima

A multicenter, double-blind, randomized controlled trial of a new antiviral drug for COVID-19.

Michael Dube  
Heinz-Josef Lenz  

Phase II study of anti-inflammatory/antiviral therapy in moderate-severe pre-ventilator COVID-19.

Michael Dube  

A5395: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19.

Luanda Grazette  

Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically Ill COVID-19 Patients

Julie Lang  
Kashif Khan  
Zea Borok  
Perren Cobb  

The I-SPY COVID TRIAL is a platform trial providing access to investigational agents for critically ill patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19. The primary endpoint will be time to reach COVID level 4 or less.

Heinz-Josef Lenz  

An open-label, pilot study followed by a randomized phase II trial of antiviral therapy combined with baricitinib or antivirals alone in moderate and severe patients with COVID-19.

Meghan Lewis  

A Phase 3, Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients with COVID-19 Pneumonia.

Caroline Piatek  

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Adupa P Rao  

A phase 3 randomized placebo controlled study to examine the efficacy and safety of DAS181 for the treatment of lower respiratory tract parainfluenza infection in the immunocompromised subjects.

Michael E. Selsted  
Andre J. Ouellette  
Paul M. Beringer  
A. Purush Rao  
William Stohl  

Developing peptide treatment for COVID-19 pneumonia. Completed Phase 1 PK and safety studies.

Norah Terrault  

A Phase II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 MG/KG or 4 MG/KG Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia